Global expansion Synthon is actively expanding its footprint in Europe with new facilities and offices in Spain and Czechia, signaling opportunities to offer regulatory, manufacturing, and supply-chain support for complex generics in regional markets.

Complex generics focus The company emphasizes complex generic medicines and oligonucleotide development, suggesting partnerships around advanced APIs, specialty therapies, and high-value generics where collaborators can leverage Synthon's R&D and manufacturing capabilities.

Strategic collaborations Recent licensing and supply agreements, including the Ozanimod capsule deal with Zydus Group, indicate openness to co-development and licensing models that can be extended to other high-demand generic assets or niche therapies.

Global regulatory reach Regulatory approvals in over 90 countries and a diversified sales approach via partnerships and select direct sales create opportunities to propose regional market access, registration support, and supply reliability for new products.

Sustainability and credibility Recognition such as the EcoVadis Silver Medal and Top Employers Spain enhances credibility with sustainability- and quality-conscious buyers, making a compelling case for solutions that align with ESG and corporate governance in procurement conversations.